Ensaio de fase 2 para avaliar a segurança e imunogenicidade de uma vacina pneumocócica conjugada 25-valente (IVT-PCV25) em lactentes
InfectologiaResumo original em inglês
O que aconteceu
IVT-PCV25 is a 25-valent pneumococcal conjugate vaccine designed to broaden serotype coverage beyond current vaccines. We evaluated the safety and immunogenicity in infants of three dose-ranging formulations of IVT-PCV25 in comparison to licensed Prevnar-20.
In this double-blind phase 2 trial in the Philippines, 421 healthy infants were randomly assigned (1:1:1:1) to three IVT-PCV25-formulation arms or a Prevnar-20 arm. Three doses were administered 4-weeks apart from 6 weeks of age, alongside routine vaccinations. Adverse events (AEs), and IgG and functional antibody (opsonophagocytic; OPA) titres were assessed up to 28-days after Dose 3. Unlike IgG concentrations, OPA titres were only measured in a third of the population.
O que encontraram
Solicited local and systemic AEs were reported for 90-93% and 94-99% of IVT-PCV25 recipients, respectively, and for 84% and 97% of Prevnar-20 recipients, respectively. These AEs were predominantly mild or moderate, and transient. No serious AE was attributed to IVT-PCV25. All formulations of IVT-PCV25 appeared immunogenic by IgG assay or OPA, or both. IgG GMTs to 19/25 serotype antigens were above the aggregate correlate-of-protection threshold of 0.35 μg/mL; and for the other 6/25 serotypes, the OPA GMTs were > 50-fold the lower limit of quantification (8 dil-1). No clear dose effect was observed. A 2-fold change in antigen quantity only led to a corresponding 2-fold antibody response for four serotypes, and by OPA only. In Prevnar-20 recipients, IgG GMCs were ≥ 0.85 μg/mL for all shared serotypes.
Por que isso importa
In infants, IVT-PCV25 had an acceptable safety profile. Although the results suggest that IVT-PCV25 has the potential to broaden serotype coverage, there is scope for formulation optimisation by rebalancing serotype-antigen quantities.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Phase 2 trial to evaluate the safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine (IVT-PCV25) in infants
Lulu Bravo, Nancy Bermal, Edison Alberto, January Anne Pardo, Maria Angela Maronilla, Maria Christine Joy Tanteo, Sue Ann Clemens, Frank W Rockhold, Indah Andi-Lolo, Rohan J Vilms et al.
Descritores MeSH
- Immunogenicity, Vaccine
- Pneumococcal Infections
- Pneumococcal Vaccines
- Female
- Humans
- Immunoglobulin G
- Infant
- Male
- Philippines
- Vaccines, Conjugate
Veja também
Estudos relacionados
- A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older
- Seroeficácia de uma vacina pneumocócica conjugada 10-valente (Pneumosil®) em comparação com outras vacinas pneumocócicas conjugadas em crianças
- Os efeitos mútuos na segurança e imunogenicidade da vacinação combinada com a vacina pneumocócica conjugada 15-valente e adsorvida DPT acelular em lactentes saudáveis de 3 meses: Ensaio clínico de fase III, randomizado, aberto, controlado
- Um estudo de fase 3, randomizado para avaliar a segurança, tolerabilidade e imunogenicidade de V116 em crianças e adolescentes com risco aumentado de doença pneumocócica (STRIDE-13)
- Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials
- Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial